Ben Zimmerman Email & Phone Number

2500 Valby, Dk

Global forecasting and analytics across the entire portfolio in oncology, hematology, immunology, and inflammation.

Lawrence Township, Nj, Us

Lead a team of >10 in Princeton, UK, and Switzerland and >25 in India focused on international commercial revenue forecasting, performance, and market research across BMS's full portfolio in hematology, solid tumor oncology, cardiovascular, and immunology.

Lawrence Township, Nj, Us

Portfolio Lead for Worldwide Oncology Commercialization within Enterprise Strategy and Performance

Lawrence Township, Nj, Us

Forecasting for Opdivo, Yervoy, and oncology pipeline assets across many solid tumor types including NSCLC, GI, and others.

Lawrence Township, Nj, Us

Led US forecasting efforts for a multi-billion dollar portfolio of therapies treating Hepatitis C and HIV: Daklinza, Atripla, Sustiva, Reyataz, and Evotaz

Evanston, Il, Us

Notable ProjectsForecasting• Two years of experience forecasting new indications of an existing biologic product in the US, Canada, and EU• Led full day training sessions in nine Latin American affiliate offices of a global biotech• Rebuilt two multi-billion dollar forecast models from scratch and supported two 10 year forecast cycles for both brands• Supported six business development and licensing efforts with forecasts in the cardiovascular and eye care therapy areasAnalytics• Led a team of 11 consultants supporting eight direct clients with reporting and ad hoc analytics• Interviewed 20+ brand and analytics stakeholders to evaluate and implement a new methodology to split $1B+ of revenue by indication using chart audit and secondary sales data• Utilized logistic regression analysis with >130 variables to find predictors of purchasing a biologic product post-launchProduct Launch Market Research• Estimated the value of four new indications for a multi-billion dollar product via 70 qualitative interviews with physicians and patients and a 300 physician quantitative survey• Estimated the impact of a black box warning on a launch product• Conducted a 600 physician quantitative market research study across ICO-6 countries with advanced conjoint analysis for a pre-launch injectableSales Force Effectiveness• Identified drivers of sales force effectiveness for a female reproductive health medical device based on 75 interviews, sales representative ridealongs, and a 120 rep survey• Optimized market coverage for a flame-resistant clothing manufacturer that lead to the creation of an inside sales force, two new sales force roles, and several thousand leadsManaged Care• Quantified payer restrictiveness across commercial and Part D payers then developed heat maps showing restrictiveness by MSA• Studied global willingness to pay for a pre-launch biologic product via 180 qualitative interviews in Russia, Poland, Spain, Japan, China, and Brazil